Sponsor: MUSC
Sponsor Study ID: 103970
Study Title: Double Blind Randomized Controlled Trial Comparing Suvorexant 20 Mg to Placebo for Treatment of Insomnia in Cancer Survivors
CTO #: 103970
NCT Number: NCT06162663
Phase: IV
Protocol Type: Supportive Care
Age Group: Adults
Disease Sites: Breast
Study Objectives: 1. To evaluate the self-reported efficacy of suvorexant for the treatment of insomnia in breast cancer survivors at least 6 weeks beyond completion of definitive treatment and less than 5 years from time of initial diagnosis. 2. To assess the impact of suvorexant on quality of life in breast cancer survivors.